Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Official Publications ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Delayed Hong Kong S.E.
Other stock markets
 03:11:30 2024-05-23 am EDT 		5-day change 1st Jan Change
14.28 HKD -1.24% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. -1.38% -52.24%
May. 17 Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China MT
May. 17 Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS) CI

Official Publications

No official publication found

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies
  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
  5. Official Publications